CliffBio
biologic

Xgeva

denosumab

Loss of exclusivityNovember 2022projected — 12-year biologic exclusivity estimate
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameXgeva
Active ingredientdenosumab
Strength120MG/1.7ML (70MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalNovember 2010
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Xgeva patent cliff — loss of exclusivity November 2022 | CliffBio